188 related articles for article (PubMed ID: 19501402)
1. Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development.
Gancz D; Fishelson Z
Mol Immunol; 2009 Sep; 46(14):2794-800. PubMed ID: 19501402
[TBL] [Abstract][Full Text] [Related]
2. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59.
Ziller F; Macor P; Bulla R; Sblattero D; Marzari R; Tedesco F
Eur J Immunol; 2005 Jul; 35(7):2175-83. PubMed ID: 15971270
[TBL] [Abstract][Full Text] [Related]
3. Immunization against tumor cell surface complement-regulatory proteins.
Durrant LG; Spendlove I
Curr Opin Investig Drugs; 2001 Jul; 2(7):959-66. PubMed ID: 11757799
[TBL] [Abstract][Full Text] [Related]
4. Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma.
Macor P; Mezzanzanica D; Cossetti C; Alberti P; Figini M; Canevari S; Tedesco F
Cancer Res; 2006 Apr; 66(7):3876-83. PubMed ID: 16585216
[TBL] [Abstract][Full Text] [Related]
5. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q
Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181
[TBL] [Abstract][Full Text] [Related]
6. Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59.
Clayton A; Harris CL; Court J; Mason MD; Morgan BP
Eur J Immunol; 2003 Feb; 33(2):522-31. PubMed ID: 12645951
[TBL] [Abstract][Full Text] [Related]
7. Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab.
Terui Y; Sakurai T; Mishima Y; Mishima Y; Sugimura N; Sasaoka C; Kojima K; Yokoyama M; Mizunuma N; Takahashi S; Ito Y; Hatake K
Cancer Sci; 2006 Jan; 97(1):72-9. PubMed ID: 16367924
[TBL] [Abstract][Full Text] [Related]
8. Cell-surface density of complement restriction factors (CD46, CD55, and CD59): oral squamous cell carcinoma versus other solid tumors.
Ravindranath NM; Shuler C
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Feb; 103(2):231-9. PubMed ID: 17234541
[TBL] [Abstract][Full Text] [Related]
9. Expression of complement system regulatory molecules in the endometrium of normal ovulatory and hyperstimulated women correlate with menstrual cycle phase.
Nogawa Fonzar-Marana RR; Ferriani RA; Soares SG; Cavalcante-Neto FF; Teixeira JE; Barbosa JE
Fertil Steril; 2006 Sep; 86(3):758-61. PubMed ID: 16831436
[TBL] [Abstract][Full Text] [Related]
10. [Research progression on complement regulatory proteins CD46, CD55, and CD59 in tumor immunotherapy].
Qin C; Cai XY
Ai Zheng; 2006 Nov; 25(11):1450-3. PubMed ID: 17094920
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B virus sensitizes hepatocytes to complement-dependent cytotoxicity through downregulating CD59.
Qu Z; Liang X; Liu Y; Du J; Liu S; Sun W
Mol Immunol; 2009 Dec; 47(2-3):283-9. PubMed ID: 19804910
[TBL] [Abstract][Full Text] [Related]
12. Functional analysis of CD59 using complement-dependent cytotoxicity assay.
Kolev M
Methods Mol Biol; 2014; 1100():347-53. PubMed ID: 24218274
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic inhibition of the complement system.
Makrides SC
Pharmacol Rev; 1998 Mar; 50(1):59-87. PubMed ID: 9549758
[TBL] [Abstract][Full Text] [Related]
14. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies.
Iannello A; Ahmad A
Cancer Metastasis Rev; 2005 Dec; 24(4):487-99. PubMed ID: 16408158
[TBL] [Abstract][Full Text] [Related]
15. Complement regulatory proteins and autoimmunity.
Song WC
Autoimmunity; 2006 Aug; 39(5):403-10. PubMed ID: 16923540
[TBL] [Abstract][Full Text] [Related]
16. Complement regulatory proteins (CD46, 55 and 59) expressed on Schwann cells: immune targets in demyelinating neuropathies?
Miyaji K; Paul F; Shahrizaila N; Umapathi T; Yuki N
J Neuroimmunol; 2014 Nov; 276(1-2):172-4. PubMed ID: 25156074
[TBL] [Abstract][Full Text] [Related]
17. Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid.
Donin N; Jurianz K; Ziporen L; Schultz S; Kirschfink M; Fishelson Z
Clin Exp Immunol; 2003 Feb; 131(2):254-63. PubMed ID: 12562385
[TBL] [Abstract][Full Text] [Related]
18. Targeted delivery of siRNA using transferrin-coupled lipoplexes specifically sensitizes CD71 high expressing malignant cells to antibody-mediated complement attack.
Cinci M; Mamidi S; Li W; Fehring V; Kirschfink M
Target Oncol; 2015 Sep; 10(3):405-13. PubMed ID: 25395366
[TBL] [Abstract][Full Text] [Related]
19. ''Homologous restriction'' in complement lysis: roles of membrane complement regulators.
Morgan BP; Berg CW; Harris CL
Xenotransplantation; 2005 Jul; 12(4):258-65. PubMed ID: 15943774
[TBL] [Abstract][Full Text] [Related]
20. Complement-dependent cytotoxicity induced by therapeutic antibodies in B-cell acute lymphoblastic leukemia is dictated by target antigen expression levels and augmented by loss of membrane-bound complement inhibitors.
Loeff FC; van Egmond HME; Nijmeijer BA; Falkenburg JHF; Halkes CJ; Jedema I
Leuk Lymphoma; 2017 Sep; 58(9):1-14. PubMed ID: 28140725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
